Floatz logo

Dimethyloxobuthylphosphonilmethylate

Cerebrovascular Disorders

Tatchempharmpreparaty, JSCSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Cerebrovascular Disorders cohort.

Asset / SponsorPhaseRating
WARFARIN
Seoul National University Hospital
Phase 4BBB
Acetylsalicylic Acid
Peking Union Medical College Hospital
Phase 3BB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Zhejiang Provincial People's Hospital
Phase 3BB
Lipitor
Sichuan Provincial People's Hospital
Phase 4BB
Plavix
Peking Union Medical College Hospital
Phase 3BB

View all 37 →

Same molecule, other indications

Dimethyloxobuthylphosphonilmethylate is also rated in:

Acute StrokeDormant
B
Indicative ·
60 / 100
View asset →
Physiological Effects of DrugsDormant
B
Indicative ·
60 / 100
View asset →
stroke disorderDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →